{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:46Z","timestamp":1792715866080,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108538","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:15:09Z","timestamp":1789161309000},"page":"108538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort"],"prefix":"10.1016","volume":"11","author":[{"given":"S.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-6508","authenticated-orcid":false,"given":"M.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-5731","authenticated-orcid":false,"given":"M.A.","family":"Munegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-337X","authenticated-orcid":false,"given":"B.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108538_bib1","first-page":"287","article-title":"Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN","volume":"5","author":"Zhang","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.esmoop.2026.108538_bib2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.20892\/j.issn.2095-3941.2020.0523","article-title":"Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030","volume":"18","author":"Lei","year":"2021","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.esmoop.2026.108538_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12885-024-13336-w","article-title":"Epidemiology of breast cancer in Chinese women from 1990 to 2021: a systematic analysis and comparison with the global burden","volume":"25","author":"Long","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2026.108538_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10549-022-06709-x","article-title":"Treatment of HR+\/HER2- breast cancer in urban mainland China: results from the CancerMPact Survey 2019","volume":"195","author":"Murali","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2026.108538_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2025.100567","article-title":"Capturing breast cancer subtypes in cancer registries: insights into real-world incidence and survival","volume":"44","author":"Vaz-Gon\u00e7alves","year":"2025","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.esmoop.2026.108538_bib7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108538_bib8","article-title":"Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline","volume":"10","author":"Al Sukhun","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.esmoop.2026.108538_bib9","first-page":"107","article-title":"Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)","volume":"4","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.esmoop.2026.108538_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103691","article-title":"Real-world treatment patterns and outcomes in patients with HR+\/HER2- metastatic breast cancer treated with chemotherapy in the United States","volume":"9","author":"Tolaney","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108538_bib11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41571-022-00685-3","article-title":"Mitigating acute chemotherapy-associated adverse events in patients with cancer","volume":"19","author":"Kuderer","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108538_bib14","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108538_bib15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.108538_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108538_bib21","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108538_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108538_bib25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.annonc.2025.12.017","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone-receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study","volume":"37","author":"Pistilli","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108538_bib26","series-title":"Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2\u2013) breast cancer: patient-reported outcomes (PROs) from the TROPION-Breast01 study. Oral presentation 1006","author":"Pernas","year":"2024"},{"key":"10.1016\/j.esmoop.2026.108538_bib27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11523-021-00838-x","article-title":"An overview of the treatment efficacy and side effect profile of pharmacological therapies in Asian patients with breast cancer","volume":"16","author":"Lu","year":"2021","journal-title":"Target Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.108538_bib28","article-title":"Clinical outcomes of chemotherapy in cancer patients with different ethnicities","volume":"6","author":"Pathak","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.esmoop.2026.108538_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2217\/fon-2023-0188","article-title":"TROPION-Breast01: datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+\/HER2\u2212 breast cancer","volume":"20","author":"Bardia","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2026.108538_bib30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline update","volume":"144","author":"Allison","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.esmoop.2026.108538_bib31","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.esmoop.2026.108538_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2026.108538_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108330","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive HER2 negative breast cancer: safety and patient-reported outcomes from the phase III TROPION Breast01 study","volume":"11","author":"Rugo","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108538_bib34","series-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.esmoop.2026.108538_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2024.03.1930","article-title":"PCR50 Estimating meaningful change thresholds (MCTs) for EORTC Scales in a phase 3 trial in participants with inoperable or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer","volume":"27","author":"Zhu","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.esmoop.2026.108538_bib36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10549-015-3342-2","article-title":"Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome","volume":"150","author":"Raphael","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2026.108538_bib38","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s13063-023-07730-1","article-title":"How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review","volume":"24","author":"Royle","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.esmoop.2026.108538_bib39","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1038\/s41467-025-59210-6","article-title":"Capivasertib plus fulvestrant in patients with HR-positive\/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort","volume":"16","author":"Hu","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.108538_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study","volume":"16","author":"Cheng","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmoop.2026.108538_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lungcan.2023.01.013","article-title":"NEPTUNE China cohort: first-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer","volume":"178","author":"Cheng","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.108538_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.esmoop.2026.108538_bib43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12955-019-1220-z","article-title":"The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis","volume":"17","author":"Rivera","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.esmoop.2026.108538_bib44","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108538_bib45","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s12282-024-01600-7","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in previously treated Asian patients with HER2-low unresectable\/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study","volume":"31","author":"Yamashita","year":"2024","journal-title":"Breast Cancer"},{"key":"10.1016\/j.esmoop.2026.108538_bib46","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","article-title":"Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial","volume":"30","author":"Xu","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2026.108538_bib47","first-page":"S1683","volume":"36","author":"Fan","year":"2025","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602483X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602483X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:41:09Z","timestamp":1792712469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292602483X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S205970292602483X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108538","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108538"}}